# Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction

> **NCT02795637** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)
- Binge-Eating Disorder Disorder

## Interventions

- **DRUG:** dasotraline

## Key facts

- **NCT ID:** NCT02795637
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2016-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795637, "Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02795637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*